Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN
Founder-led company
Supernus Pharmaceuticals stock price today
$41.17
+3.99
+10.73%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Supernus Pharmaceuticals stock price monthly change
+29.91%
month
Supernus Pharmaceuticals stock price quarterly change
+29.91%
quarter
Supernus Pharmaceuticals stock price yearly change
+25.27%
year
Supernus Pharmaceuticals key metrics
Market Cap | 1.95B |
Enterprise value | 2.33B |
P/E | 34.1 |
EV/Sales | 3.50 |
EV/EBITDA | 15.37 |
Price/Sales | 2.98 |
Price/Book | 2.24 |
PEG ratio | 2.87 |
EPS | -0.28 |
Revenue | 597.40M |
EBITDA | 93.75M |
Income | -15.50M |
Revenue Q/Q | -6.58% |
Revenue Y/Y | -10.63% |
Profit margin | 9.1% |
Oper. margin | 6.55% |
Gross margin | 86.93% |
EBIT margin | 6.55% |
EBITDA margin | 15.69% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSupernus Pharmaceuticals stock price history
Supernus Pharmaceuticals stock forecast
Supernus Pharmaceuticals financial statements
| Jun 2023 | 135.56M | -831K | -0.61% |
|---|---|---|---|
| Sep 2023 | 153.88M | -15.97M | -10.38% |
| Dec 2023 | 164.31M | 1.17M | 0.72% |
| Mar 2024 | 143.64M | 124K | 0.09% |
| Mar 2024 | 143.64M | 124K | 0.09% |
|---|---|---|---|
| Sep 2025 | 172.2M | 38.71M | 22.48% |
| Oct 2025 | 161.85M | 28.36M | 17.53% |
| Dec 2025 | 173.75M | 36.15M | 20.81% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 1293099000 | 373.19M | 28.86% |
|---|---|---|---|
| Sep 2023 | 1285160000 | 372.96M | 29.02% |
| Dec 2023 | 1408977000 | 487.46M | 34.6% |
| Mar 2024 | 1304090000 | 374.92M | 28.75% |
| Jun 2023 | -18.87M | 60.29M | -478.91M |
|---|---|---|---|
| Sep 2023 | 35.87M | 34.63M | -230K |
| Dec 2023 | 44.95M | -65.98M | 1.09M |
| Mar 2024 | 38.40M | -51.62M | 1.57M |
Supernus Pharmaceuticals alternative data
| Aug 2023 | 612 |
|---|---|
| Sep 2023 | 612 |
| Oct 2023 | 612 |
| Nov 2023 | 612 |
| Dec 2023 | 612 |
| Jan 2024 | 612 |
| Feb 2024 | 612 |
| Mar 2024 | 652 |
| Apr 2024 | 652 |
| May 2024 | 652 |
| Jun 2024 | 652 |
| Jul 2024 | 652 |
Supernus Pharmaceuticals other data
49.75%
-50.25%
of SUPN is owned by hedge funds
169
-86
30.68M
-25.13M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 5000 |
| Mar 2024 | 0 | 93505 |
| Sep 2024 | 0 | 10000 |
| Nov 2024 | 0 | 309422 |
| Dec 2024 | 0 | 12745 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | BHATT PADMANABH P. officer: Sr. VP o.. | Common Stock | 12,745 | $25.3 | $322,449 | ||
Option | BHATT PADMANABH P. officer: Sr. VP o.. | Common Stock | 12,745 | $25.3 | $322,449 | ||
Option | BHATT PADMANABH P. officer: Sr. VP o.. | Common Stock | 8,750 | $23.99 | $209,913 | ||
Option | BHATT PADMANABH P. officer: Sr. VP o.. | Common Stock | 8,750 | $23.99 | $209,913 | ||
Sale | BHATT PADMANABH P. officer: Sr. VP o.. | Common Stock | 12,745 | $36.68 | $467,487 | ||
Sale | BHATT PADMANABH P. officer: Sr. VP o.. | Common Stock | 12,745 | $36.68 | $467,487 | ||
Option | BHATT PADMANABH P. officer: Sr. VP o.. | Employee Stock Option (Right to Buy) | 21,495 | $24.65 | $529,744 | ||
Option | BHATT PADMANABH P. officer: Sr. VP o.. | Employee Stock Option (Right to Buy) | 21,495 | $24.65 | $529,744 | ||
Option | NEWHALL CHARLES W III director | Common Stock | 20,000 | $9.13 | $182,600 | ||
Sale | NEWHALL CHARLES W III director | Common Stock | 10,700 | $36.24 | $387,768 |
| Patent |
|---|
Application Filling date: 12 Apr 2022 Issue date: 28 Jul 2022 |
Grant Filling date: 19 Nov 2019 Issue date: 7 Jun 2022 |
Grant Filling date: 6 Jun 2017 Issue date: 10 May 2022 |
Application Filling date: 4 Aug 2021 Issue date: 27 Jan 2022 |
Grant Filling date: 23 Apr 2021 Issue date: 9 Nov 2021 |
Application Filling date: 25 Jun 2021 Issue date: 21 Oct 2021 |
Application Filling date: 27 Oct 2020 Issue date: 7 Oct 2021 |
Grant Filling date: 30 Apr 2020 Issue date: 14 Sep 2021 |
Application Filling date: 23 Apr 2021 Issue date: 5 Aug 2021 |
Grant Filling date: 30 Oct 2018 Issue date: 3 Aug 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
Supernus Pharmaceuticals: Derisked CNS Drug Portfolio Offers Attractive Buying Opportunity
Volume Breakout Report Update: Buy Eton Pharmaceuticals
Volume Breakout Report: August 20, 2022 (Technical Analysis)
Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio
Supernus Pharmaceuticals: Virtuous Cycle Of Free Cash Flow Generation To Fund Product Development And Acquisition
-
What's the price of Supernus Pharmaceuticals stock today?
One share of Supernus Pharmaceuticals stock can currently be purchased for approximately $41.17.
-
When is Supernus Pharmaceuticals's next earnings date?
Unfortunately, Supernus Pharmaceuticals's (SUPN) next earnings date is currently unknown.
-
Does Supernus Pharmaceuticals pay dividends?
No, Supernus Pharmaceuticals does not pay dividends.
-
How much money does Supernus Pharmaceuticals make?
Supernus Pharmaceuticals has a market capitalization of 1.95B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 8.95% to 607.52M US dollars.
-
What is Supernus Pharmaceuticals's stock symbol?
Supernus Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "SUPN".
-
What is Supernus Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Supernus Pharmaceuticals?
Shares of Supernus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Supernus Pharmaceuticals's key executives?
Supernus Pharmaceuticals's management team includes the following people:
- Mr. Jack A. Khattar Founder, Pres, Chief Executive Officer, Sec. & Director(age: 64, pay: $1,680,000)
- Dr. Padmanabh P. Bhatt Chief Scientific Officer & Senior Vice President of Intellectual Property(age: 68, pay: $582,200)
- Ms. Tami T. Martin Senior Vice President of Regulatory Affairs(age: 70, pay: $495,200)
-
Is Supernus Pharmaceuticals founder-led company?
Yes, Supernus Pharmaceuticals is a company led by its founder Mr. Jack A. Khattar.
-
How many employees does Supernus Pharmaceuticals have?
As Jul 2024, Supernus Pharmaceuticals employs 652 workers.
-
When Supernus Pharmaceuticals went public?
Supernus Pharmaceuticals, Inc. is publicly traded company for more then 13 years since IPO on 1 May 2012.
-
What is Supernus Pharmaceuticals's official website?
The official website for Supernus Pharmaceuticals is supernus.com.
-
Where are Supernus Pharmaceuticals's headquarters?
Supernus Pharmaceuticals is headquartered at 9715 Key West Avenue, Rockville, MD.
-
How can i contact Supernus Pharmaceuticals?
Supernus Pharmaceuticals's mailing address is 9715 Key West Avenue, Rockville, MD and company can be reached via phone at +30 18382500.
Supernus Pharmaceuticals company profile:
Supernus Pharmaceuticals, Inc.
supernus.comExchange:
NASDAQ
Full time employees:
652
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
9715 Key West Avenue
Rockville, MD 20850
Rockville, MD 20850
CIK: 0001356576
ISIN: US8684591089
CUSIP: 868459108
